Dr Amee George, Manager, ACRF Target and Drug Discovery Platform, JCSMR
High throughput screening (HTS) is a way of rapidly assessing a large number of candidate compounds or genetic modulators to identify those which can modulate a particular biological or chemical process. Often requiring sophisticated robotics, imaging and computational analysis, HTS is able to provide significant insights into normal and disease biology, as well as assist in the development of therapeutic drugs to treat disease. My talk will give an outline of the requirements for HTS, as well as provide some specific examples of some high throughput screens that I have performed utilising this technology. I will also discuss the new ACRF Target and Drug Discovery platform at the JCSMR, giving an overview of the equipment and the types of assays that can be performed using this instrumentation.
Dr Amee George obtained her PhD in 2007 from the Department of Pathology at the University of Melbourne. Early on in her career, Dr George developed a keen interest in the use of functional genomics-based approaches to investigate the molecular basis of disease. In 2008, she commenced her postdoctoral studies in a joint appointment with the University of Queensland and the Peter MacCallum Cancer Centre (Victorian Centre for Functional Genomics) in Melbourne focusing on developing and undertaking high throughput functional and compound screens to identify the molecular basis underlying disease. In April 2015, she moved to the JCSMR at ANU in the ACRF Department of Cancer Biology and Therapeutics to continue her research, and played an instrumental role in setting up the new ACRF Target and Drug Discovery platform located at the JCSMR, of which she now manages